@article {7070,
	title = {Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma},
	journal = {Leukemia and Lymphoma},
	volume = {57},
	year = {2016},
	note = {Cited By :1Export Date: 18 February 2017References: Richardson, R.G., Schlossman, R.L., Weller, E., Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. myeloma (2002) Blood, 100, pp. 3063-3067;Weber, D.M., Chen, C., Niesvizky, R., Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America (2007) N Engl J Med, 357, pp. 2133-2142; 
Dimopoulos, M., Spencer, A., Attal, M., Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma (2007) N Engl J Med, 357, pp. 2123-2132; 
Benboubker, L., Dimopoulos, M.A., Dispenzieri, A., Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma (2014) N Engl J Med, 371, pp. 906-917; 
Palumbo, A., Hajek, R., Delforge, M., Continuous lenalidomide treatment for newly diagnosed multiple myeloma (2012) N Engl J Med, 366, pp. 1759-1769; 
Davies, F.E., Raje, N., Hideshima, T., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma (2001) Blood, 98, pp. 210-216; 
Lentzsch, S., LeBlanc, R., Podar, K., Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo (2003) Leukemia, 17, pp. 41-44; 
Mitsiades, N., Mitsiades, C.S., Poulaki, V., Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications (2002) Blood, 99, pp. 4525-4530; 
Dimopoulos, M.A., Chen, C., Spencer, A., Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (2009) Leukemia, 23, pp. 2147-2152; 
Rajkumar, S.V., Jacobus, S., Callander, N.S., Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial (2010) Lancet Oncol, 11, pp. 29-37; 
Levey, A.S., Bosch, J.P., Lewis, J.B., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation (1999) Modification of Diet in Renal Disease Study Group. Ann Intern Med, 130, pp. 461-470; 
Durie, B.G., Harousseau, J.L., Miguel, J.S., International myeloma working group. International uniform response criteria for multiple myeloma (2006) Leukemia, 20, pp. 1467-1473; 
Gandhi, A.K., Kang, J., Capone, L., Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function (2010) Curr Cancer Drug Targets, 10, pp. 155-167; 
Hsu, A.K., Quach, H., Tai, T., The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy (2011) Blood, 117, pp. 1605-1613; 
Reece, D., Kouroukis, C.T., Leblanc, R., Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus (2012) Adv Hematol, 2012; 
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (2015) N Engl J Med, 372, pp. 142-152; 
Lonial, S., Vij, R., Harousseau, J.L., Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma (2012) J Clin Oncol, 30, pp. 1953-1959; 
Chen, C., Reece, D.E., Siegel, D., Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma (2009) Br J Haematol, 146, pp. 164-170; 
van de Donk, N.W., G{\"o}rg{\"u}n, G., Groen, R.W., Lenalidomide for the treatment of relapsed and refractory multiple myeloma (2012) Cancer Manag Res, 4, pp. 253-268; 
Dimopoulos, M.A., Terpos, E., Niesvizky, R., How lenalidomide is changing the treatment of patients with multiple myeloma (2013) Crit Rev Oncol Hematol, 88, pp. S23-S35; 
Scott, L.J., Lyseng-Williamson, K.A., Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma (2011) Drugs, 71, pp. 625-649; 
San Miguel, J.F., Dimopoulos, M., Weber, D., Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis) [abstract] (2007) Blood, 110, p. 2712; 
Chen, C., Baldassarre, F., Kanjeekal, S., Lenalidomide in multiple myeloma-a practice guideline (2013) Curr Oncol, 20, pp. e136-e149; 
Dimopoulos, M., Alegre, A., Stadtmauer, E.A., The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function (2010) Cancer, 116, pp. 3807-3814; 
Dimopoulos, M.A., Roussou, M., Gkotzamanidou, M., The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma (2013) Leukemia, 27, pp. 423-429; 
Dimopoulos, M.A., Terpos, E., Chanan-Khan, A., Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group (2010) J Clin Oncol, 28, pp. 4976-4984
},
	month = {2016},
	pages = {1776 - 1780},
	abstract = {Abstract: To compare the outcomes of patients with relapsed or refractory multiple myeloma (RRMM) who were treated with lenalidomide combined with high versus low dose of dexamethasone. One hundred forty consecutive relapsed or refractory multiple myeloma (RRMM) patients who received lenalidomide with dexamethasone, in two consecutive time periods, were divided into two groups: group RD (70 consecutive patients in the first period) who received lenalidomide with intermediate doses of dexamethasone and group Rd (70 consecutive patients in the more recent period) who received lenalidomide with low-dose dexamethasone. 62\% and 73\% of patients who received RD and Rd (p = 0.148) achieved at least a partial response, accordingly. The median OS was 20 and 41 months for the RD and the Rd group, accordingly. In the multivariate analysis, Rd was associated with improved PFS. More patients treated with RD developed grade 3\&4 neutropenia and fatigue. It seems that Rd is at least as effective as RD. {\textcopyright} 2016 Informa UK Limited, trading as Taylor \& Francis Group.},
	keywords = {Dexamethasone, doses, Lenalidomide, multiple myeloma},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959238168\&doi=10.3109\%2f10428194.2016.1151513\&partnerID=40\&md5=9222a2869121fa66f24dc20bf43ceacd},
	author = {Zagouri, F. and Roussou, M. and Kastritis, E. and Gavriatopoulou, M. and Eleutherakis-Papaiakovou, E. and Kanellias, N. and Kalapanida, D. and Christoulas, D. and Migkou, M. and Terpos, E. and Dimopoulos, M.A.}
}
